Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
作者信息
Florentino Pilar T V, Alves Flávia J O, Cerqueira-Silva Thiago, de Araújo Oliveira Vinicius, Júnior Juracy B S, Penna Gerson O, Boaventura Viviane, Werneck Guilherme L, Pearce Neil, Rodrigues Laura C, Barreto Mauricio L, Barral-Netto Manoel, Paixão Enny S
机构信息
Centre of Data and Knowledge Integration for Health, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil; Biomedical Science Institute, University of São Paulo, São Paulo, 41745-715 Brazil.
Centre of Data and Knowledge Integration for Health, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil.
出版信息
Lancet Infect Dis. 2022 Dec;22(12):1669-1670. doi: 10.1016/S1473-3099(22)00728-9. Epub 2022 Nov 7.
Abstract
摘要
相似文献
1
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
Lancet Infect Dis. 2022 Dec;22(12):1669-1670. doi: 10.1016/S1473-3099(22)00728-9. Epub 2022 Nov 7.
2
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Front Immunol. 2022 Jun 9;13:918896. doi: 10.3389/fimmu.2022.918896. eCollection 2022.
3
Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Emerg Microbes Infect. 2022 Dec;11(1):1343-1345. doi: 10.1080/22221751.2022.2072773.
4
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
5
SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
J Med Virol. 2022 Aug;94(8):3768-3775. doi: 10.1002/jmv.27794. Epub 2022 Apr 23.
6
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
BMC Med. 2022 Jun 9;20(1):216. doi: 10.1186/s12916-022-02406-0.
7
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.
8
Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
EBioMedicine. 2023 Feb;88:104446. doi: 10.1016/j.ebiom.2023.104446. Epub 2023 Jan 25.
9
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
10
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826. doi: 10.1093/cid/ciab1041.
引用本文的文献
1
Text mining method to unravel long COVID's clinical condition in hospitalized patients.
Cell Death Dis. 2024 Sep 13;15(9):671. doi: 10.1038/s41419-024-07043-4.
2
Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
Drug Saf. 2024 Oct;47(10):991-1010. doi: 10.1007/s40264-024-01458-w. Epub 2024 Jul 15.
3
Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil.
Int J Epidemiol. 2023 Dec 25;52(6):1708-1715. doi: 10.1093/ije/dyad120.
本文引用的文献
1
Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel.
Nat Commun. 2022 Nov 15;13(1):6961. doi: 10.1038/s41467-022-34605-x.
2
Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
JAMA Netw Open. 2022 Sep 1;5(9):e2233273. doi: 10.1001/jamanetworkopen.2022.33273.
3
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.
Nat Commun. 2022 Jul 18;13(1):4154. doi: 10.1038/s41467-022-31839-7.
4
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.
5
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
Nature. 2022 Feb;602(7898):654-656. doi: 10.1038/s41586-021-04387-1. Epub 2021 Dec 23.
6
Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
Lancet. 2022 Jan 1;399(10319):25-35. doi: 10.1016/S0140-6736(21)02754-9. Epub 2021 Dec 20.
7
A Test-Negative Design with Additional Population Controls Can Be Used to Rapidly Study Causes of the SARS-CoV-2 Epidemic.
Epidemiology. 2020 Nov;31(6):836-843. doi: 10.1097/EDE.0000000000001251.
Zotero 插件